Business Wire

PUMA

13.3.2024 12:27:35 CET | Business Wire | Press release

Share
PUMA Reduces Greenhouse Gas Emissions by 24% in 2023

Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313721861/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth. (Photo: Business Wire)

This was made possible by its core suppliers doubling their use of renewable energy in 2023 compared to the previous year, increasing the use of less carbon intensive materials in its products, the introduction of low carbon shipment tariffs by PUMA’s logistics partner Maersk, by using renewable electricity or purchasing renewable energy certificates at its own operations and by investing in electric vehicles in its car fleet. Compared with the 2017 baseline, this means an absolute greenhouse gas emission reduction of 29%.

“We are very proud of the progress we have achieved on our sustainability journey in 2023, particularly when it comes to the reduction of greenhouse gases,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We will not stop there, however, and continue to execute our FOREVER.BETTER. sustainability strategy and our 10FOR25 targets.”

With an 85% reduction of own emissions and a 65% reduction of supply chain emissions relative to sales, PUMA achieved its first science-based greenhouse gas reduction target in 2023, seven years ahead of the target year 2030. PUMA’s new climate goals, which were approved by the Science Based Targets Initiative (SBTi), aim to reduce PUMA’s emissions by what scientists say is necessary to keep global warming below 1.5 degrees. By 2030, PUMA aims to reduce its absolute Scope 1 and 2 GHG emissions by 90% from a 2017 baseline year. The SBTi has classified PUMA Scope 1 and 2 targets as in line with a 1.5-degree trajectory. By 2030, PUMA also commits to reduce absolute Scope 3 GHG emissions from its supply chain and logistics by 33% compared to 2017.

Apart from increasing its climate ambitions, PUMA also made progress with its other 10FOR25 sustainability targets, reaching two out of ten targets ahead of schedule.

PUMA met its Plastics and the Oceans target by eliminating plastic carrier bags from its owned and operated stores and through researching biodegradable plastic options. An important part of this target was PUMA’s successful RE:SUEDE experiment, where it turned an experimental version of its classic Suede sneaker into compost under controlled industrial conditions. A commercial version will be launched in April 2024.

It also achieved its Human Rights target by training more than 220,000 factory workers on women’s empowerment and completely mapping subcontractors and Tier 2 suppliers for human rights risks. In addition, PUMA employees donated over 57,000 of community engagement hours.

Other progress included scaling up the use of recycled materials in 2023, producing 8 out of 10 products with a significant part of recycled or certified materials. Starting 2024, all* of PUMA’s replica football jerseys will be made using PUMA’s RE:FIBRE recycling technology which focuses on polyester textile waste as the primary source of material.

PUMA’s sustainability report is available at https://about.puma.com/en/sustainability/reporting

*excluding any locally sourced kits and replicas for Al Hilal, Galatasaray SK, Fenerbahce, Shakhtar Donetsk

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stitched. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313721861/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye